Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04993768Phase 2Completed

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Role: lead

NCT05613868Phase 2Terminated

TPN-101 in Aicardi-Goutières Syndrome (AGS)

Role: lead

NCT04993755Phase 2Unknown

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Role: lead

All 3 trials loaded